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1. Introduction 
Drug discovery and development programs are still driven by optimizing the target 
binding affinity and selectivity of the respective candidate. However, although 
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tremendous technological and methodological progress has been made, both in 
experimental and computational techniques, attrition rates remain disappointingly 
high. Besides unexpected toxicity, we often observe a lack of in vivo efficacy for 
many compounds. Such compounds appear promising in early drug discovery 
programs, but fail in later clinical trials. One of the reasons for this is the increasing 
evidence that kinetic parameters seem to correlate much better with efficacy than 
affinity does [1–4]. Considering that a considerable amount of all approved drugs 
exhibit non-equilibrium characteristics, it has been advocated that drug residence 
time may be more important for in vivo efficacy than in vitro equilibrium binding 
affinity. Furthermore, there is an increasing number of reports linking drug selectivity 
to the kinetic profile of the compound. Besides the well-known example of Tiotropium 
and the subtype selectivity profile at the five different subtypes of the muscarinic 
receptor [5,6], there was a recent report outlining the role of on-kinetics for the 
SERT/DAT selectivity of methylphenidate [7]. A correlation of in vivo efficacy with 
residence time has already been demonstrated for selected GPCRs, such as CCR5 
[8], the β-2-adrenergic receptor [9], and the A2A adenosine receptor [10]. In the 
kinase family, the dual tyrosine kinase inhibitor Lapatinib showed a long residence 
time that could be correlated with efficacy [11]. Another example is the ABL inhibitor 
Nilotinib [12]. 
Data such as these prompted David Swinney to state “These observations indicate 
that for the majority of drug targets, mass action driven equilibrium binding alone is 
not sufficient for maximal therapeutic utility” [13]. For most targets, a long residence 
time is desired. Certain proteins, however, show on-target toxicity with longer 
duration of the molecule bound to the receptor. For the D2 receptor (D2R), 
compounds possessing fast off-rates are ideal, as side effects increase drastically 
when residence time is prolonged [14,15]. Thus, the role and influence of on- and 
off-kinetics should be analyzed on a case-by-case basis.  
 
1.1. The Drug Residence Time Concept 
Since it was introduced in the scientific community in 2006, the drug-target residence 
time concept has gained in popularity [16]. In traditional in vitro methods, drug–target 
interactions have mostly been treated in terms of affinity measures or by means of 
static crystal structures of the bound complex [17]. The residence time concept, 
however, also takes into account the conformational dynamics of the protein, which 
affect drug binding and unbinding. Thus, it considers the residence time of the drug-
target complex rather than the binding affinity per se as the major contribution to in 
vivo pharmacological activity [16]. 
The binding kinetics of a drug on its protein target is characterized by the bimolecular 
association rate constant (kon), which is the rate the drug binds, and the dissociation 
rate constant (koff), which is the rate of unbinding. The sum of many effects 


































































conformational adaptation by the system [19], (iii) water rearrangements and 
changes in water networks [20,21], and (iv) shielded hydrogen bonds [22].  
Furthermore, apart from the pharmacokinetic half-life of the drug, receptor 
degradation can have an important effect on residence time in the system [23]. 
Most of the work pursued so far has focused on the dissociation kinetics of the 
ligands. However, there is increasing evidence, that the association rate should also 
be considered. A recent study of all data uploaded so far into the K4DD database 
revealed that only 0,4% of the compounds show a diffusion controlled on-rate, when 
defining diffusion control by a Kon value greater than 10
7 M-1s-1 [24,25]. Kon plays an 
important role for the in vivo translation, especially in terms of the phenomena of 
drug rebinding [26]. There are also studies on how to boost the drug-target 
association rate, e.g. by introducing polar moieties into a ligand [27]. 
 
2. K4DD – a Public Private Partnership 
The fundamental hypothesis behind the drug residence time concept is very 
appealing: A detailed understanding of the kinetics of association and dissociation of 
a target-ligand complex can provide crucial insight into the molecular mechanism of 
action of a compound. This deeper understanding might help to improve decision 
making in drug discovery, thus leading to a better selection of interesting compounds 
to be profiled further. When an initial core group of scientists from pharmaceutical 
companies decided to further explore the concept, it was soon obvious that quite a 
number of open questions needed to be addressed. These comprise the important 
aspect of small molecule optimization by analyzing molecular aspects of drug 
binding kinetics, by providing data-driven guidelines for future drug discovery, and by 
enabling rapid and robust generation of structure-kinetic data in the design-make-
test-analyze (DMTA) cycle. As these tasks go across all pharmaceutical companies 
which might consider the drug residence time concept relevant for their daily work, it 
perfectly fits the precompetitive collaboration concept of the Innovative Medicines 
Initiative (IMI) [28]. With this idea in mind, an IMI project was initiated: K4DD 
(Kinetics for Drug Discovery, www.k4dd.eu). The 5 year project with a budget of 
21M€ started in November 2012. 20 partners (9 academic institutes, 7 large 
pharmaceutical companies and 4 SMEs) from 6 European countries work closely 
together on targets that have been selected by the consortium. The approach is truly 
collaborative: Several partners contribute to the work on each target and we share 
our results in regular meetings including bi-annual meetings of the entire consortium. 
K4DD focuses on how drug binding kinetics can be influenced and how therefore 
compounds can be optimized in terms of residence time (Figure 1).  
From the outset of K4DD, it was decided to work on three scientific work packages 


































































starting point for the research in this IMI consortium. When the proposal was drafted, 
it was realized that target binding kinetics are not considered sufficiently in the 
current drug discovery process, stemming from a lack of knowledge in three 
domains, which were subsequently redefined as the work packages driving the 
K4DD consortium. WP1 is aimed at gaining a molecular understanding of kinetic 
characteristics to aid the development of predictive kinetic analyses. Partners in 
WP2 evaluate and develop technologies to enable the rapid and robust assessment 
of compounds’ kinetic characteristics. The WP3 team sees to the translation of in 
vitro data (as in WP1 and WP2) to in vivo effects, moving from intact cells to whole 
animals and men. In all cases, the consortium’s focus is on both membrane-bound 
and soluble drug targets, particularly G protein-coupled receptors, and kinases and 
proteases, respectively. The consortium has defined a target list at the very 
beginning of the five years program to ensure synergy between multiple partners that 
have actively exchanged methods and materials to speed up the research. Finding 
overall guidelines of how target interaction kinetics can be altered in the drug 
discovery process, will lead to a different approach - moving away from affinity driven 
strategies towards implementing kinetic studies at an early stage of drug discovery. 
3. New Experimental Approaches  
Reproducible and accurate experiments constitute the basis for hypothesis-driven 
research. There is a broad range of biological and biophysical assays available for 
assessing the affinity of a ligand to a macromolecule. The data generated quite often 
serve as input for computational approaches, which have become an indispensable 
tool in drug discovery and development. With the increasing amount of data 
available in the public domain, data quality, standardization, and comparability 
across different assay types have become an issue [30]. In the case of binding 
kinetics, several assays have been established and are routinely used across 
industry and academia. However, due to the need for time-resolved data collection, 
the assay panel available is limited. Furthermore, as most of the drug targets of 
current interest are membrane-bound, this poses an additional layer of complexity. 
Thus, one of the aims of K4DD is to develop new assays and to assess their 
reproducibility and comparability across different laboratories.  
3.1. Brief Overview of Existing Methods  
Although kinetic binding rate constants are increasingly accepted as important drug-
optimization metrics, respective experimental implementation has not been trivial. In 
contrast to IC50 values and other affinity based metrics, the kinetic binding rate 
constants can only be determined by measuring across multiple incubation times. 
Conventional binding measurement techniques are often not suitable for doing this in 
an efficient way, since only a single time-point is quantified per binding reaction. 



































































Over the years, Surface Plasmon Resonance (SPR) has proven to be a powerful 
approach to analyze kinetic binding rate constants of soluble drug targets. However, 
throughput is still limited, since ligands are mostly measured in series. Moreover, the 
need for purified protein, which has to be stably bound to a chip, can sometimes be 
limiting for the applicability of this approach. Especially for membrane-bound drug 
targets, purification out of the lipid environment is often difficult, making SPR 
analysis impossible. For GPCR targets, low-throughput radioligand binding 
techniques have therefore been the method of choice. Below, new advances in 
obtaining stably purified proteins and alternative methods for the continuous 
measurement of ligand binding are discussed and compared. Moreover, techniques 
are discussed in terms of usability for drug discovery. 
3.2. The Challenge of Membrane Proteins - GPCRs as a Use Case 
G-protein coupled receptors (GPCRs) represent a diverse group of membrane 
receptors that play a very important role as therapeutic targets. They are involved in 
a broad range of diseases, including diabetes, cancer, inflammation, obesity, central 
nervous system disorders and cardiovascular and respiratory diseases [31]. 
Although around 30% of all marketed drugs are directed towards GPCRs [31], there 
is still a strong need for new molecules. Especially targeting “undrugable” receptors, 
which represent valuable GPCR targets for which it has not been possible to 
discover drug candidates [32], and “orphan” receptors, whose ligands and biology 
are as yet uncharacterized [33], is of high interest. However, measurement of the 
binding kinetics of ligands to GPCRs is hampered by the difficulty of obtaining pure 
and active membrane-free receptors. 
Surface Plasmon Resonance (SPR) is a label-free technique, which requires a low 
amount of protein and is able to generate kinetics data in real time. SPR has been 
used with detergent solubilized GPCRs for kinetic profiling of compounds and for 
screening fragment libraries [34,35]. However, it is now possible to produce 
membrane proteins in reconstituted high density lipoprotein (rHDL) particles. rHDLs 
are a new technology that enables the reconstitution of membrane proteins into a 
lipidic environment close to the cell membrane making the reconstituted receptor 
very stable and highly soluble [36]. 
Within the K4DD consortium two groups have successfully reconstituted the thermo-
stabilized adenosine A2A receptor into rHDL particles and immobilized it on a SPR 
sensor chip [37,38]. Both groups compared the SPR kinetics results for the receptor 
reconstituted into rHDLs with the receptor solubilized in detergent or embedded in its 
native membrane. Bocquet et al. [38] tested different immobilization procedures 
whereas Segala and colleagues [37] focused on a large set of ligands with affinities 
ranging from 50 pM to 2 µM. These two successful studies showed that this new 
approach represents a valuable opportunity to obtain affinities and kinetics from low 
molecular weight compounds binding to GPCRs. It thus allows the characterization 


































































partitioning into detergent micelles. In addition, this system can be used to study the 
binding of ligands to GPCRs in the presence of other components such as G 
proteins. 
One of the challenges of studying binding kinetics for membrane-bound proteins is 
that it requires the removal of the proteins from their native membrane environment. 
For membrane proteins like GPCRs, the lipids within the membrane and adaptor 
proteins can have allosteric effects on the affinity and efficacy of selected ligands 
and therefore their kinetics may also be influenced [39]. Radioligand binding studies 
do not require removal of the protein from the membrane but can be time consuming 
to execute. Therefore, researchers have been looking towards new technologies to 
enable the kinetics of GPCRs to be studied in a higher throughput manner. The 
basis of these new technologies has been the development of fluorescent ligands for 
many different GPCRs and technologies that utilize them [40]. Kinetics have been 
studied either by directly monitoring the binding of the fluorescent ligand using 
confocal microscopy or by using an energy transfer based technique such as 
bioluminescence energy transfer (BRET) or time resolved fluorescence energy 
transfer (TR-FRET). Microscopy based techniques are also time consuming but do 
have the multiple advantages of using living cells, allowing dissociation kinetics to be 
measured under conditions of infinite dilution and uniquely at the single cell level. 
Binding kinetics of fluorescent ligands and allosteric influences of receptor-receptor 
interactions have been studied at the adenosine A1 and A3 receptors [41,42] and 
β­1-adrenoceptor [43] using confocal microscopy. A recently described BRET based 
assay utilizing a luciferase from a deep sea shrimp, NanoLuc, and fluorescent 
ligands has been used to investigate kinetics of a fluorescent ligand in live cells 
expressing the adenosine A1 receptor [44] and in membranes expressing free fatty 
acid receptor 1 [45]. Although to date the kinetics of unlabeled ligand have not been 
studied, this method can be used to study kinetics in living cells and membranes and 
has the potential to be a useful addition to the tool box of assays to measure binding 
kinetics of GPCRs. The TR-FRET based assay has been successfully applied to 
measure the kinetics of both labelled and unlabeled ligands at the histamine H1 
receptor [46], gonadotropin-releasing hormone (GnRH) receptor [47] and the 
dopamine D2 receptor (D2R) [48]. The study on the GnRH receptor is discussed in 
detail below (Section 3.3). For the D2R, kinetic studies using the TR-FRET assay 
were central in demonstrating that the kinetic profile of ligands may be the basis of 
bias in intracellular signaling observed [48]. The use of fluorescent ligands for 
GPCRs is thus an important new development for understanding the role of kinetics 
in receptor-drug interactions and intracellular signaling. 
In line with their importance, the structural biology of GPCRs has also been quite 
useful to visualize receptor-ligand interactions and to boost drug discovery. However, 
tThe structural basis of binding kinetics is difficult to understand and predict. An 
industry-academia collaboration within the K4DD consortium pursued by Heptares 


































































long residence time at the A2A receptor [49]. This recent study used crystallography 
and computational chemistry to investigate the dissociation rates of ligands from the 
adenosine A2A receptor. Five ligands with high affinities for the human A2A, but a 
100-fold range of dissociation rate constants were studied [50]. Five high resolution 
structures of the receptor in complex with each of these antagonists were generated, 
with a resolution ranging from 1.7 Å to 2.2 Å. Superposition of the five structures 
shows that they are identical except for a different interaction with His264 in the third 
extracellular loop (Figure 2). This histidine is involved in a salt bridge with Glu169. 
Molecular dynamics and metadynamics simulations revealed that the residence time 
of the ligands correlate with the energy required to break the salt bridge His264 - 
Glu169. Long residence time ligands appear to stabilize the Glu-His ionic interaction, 
while fast off-rate ligands were shown to destabilize this salt bridge. These results 
highlight a key determinant of the ligand-receptor binding that can be used to 
optimize receptor residence time. 
 
3.3. Comparing Different Methods - A Case Study 
The gonadotropin-releasing hormone (GnRH) receptor is involved in numerous 
hormone-dependent diseases and multiple drugs are on the market to treat e.g. 
prostate cancer [51]. The GnRH receptor is one of the targets which was accepted 
by the K4DD consortium, it served for a comparison of three different assays for 
binding kinetics. Firstly, equilibrium and kinetic binding parameters of 12 well-known 
GnRH peptide agonists were determined using a radiolabeled GnRH analogue 
displacement assay (Figure 3A) [47]. Affinity (Ki) values ranged from 13 nM for 
GnRH to 0.1 nM for Buserelin. Kinetic binding parameters were equally diverse with 
association rate constants ranging from 0.02 nM-1 min-1 for Fertirelin to 0.8 nM-1 min-1 
for Nafarelin and dissociation rate constants ranging from 0.009 min-1 for Buserelin to 
0.2 min-1 for Goserelin. Secondly, these results were compared to data obtained with 
a novel time-resolved fluorescence energy transfer (TR-FRET) assay (Figure 3B) 
and both the affinity and dissociation rate constants were highly correlated between 
both assays (R2 = 0.5, P < 0.05 for pKi values and R2 = 0.7, P < 0.0005 for pkoff 
values) [47]. Lastly, the kinetic binding parameters from both assays were translated 
to functional effects in vitro using a label-free morphological assay [52]. The 
activation profiles of endogenous GnRH (a fast dissociating agonist), and a well-
known marketed analogue Buserelin (a slow dissociating agonist) were examined. It 
was shown that Buserelin had a much higher potency than GnRH, i.e. 0.46 nM vs 17 
nM respectively. Interestingly, persistent GnRH receptor activation was observed for 
both agonists. Wash-out experiments (Figure 3C) resulted in more than 70% loss of 
signal for fast dissociating agonist GnRH, while for slow dissociating Buserelin less 
than 30% of the original response was abolished [52]. 
The use of these different protocols allowed for the first time to compare three 
diverse assays investigating qualitative and quantitative binding kinetics of a set of 


































































provided highly comparable kinetic data which in turn could be translated to wash-
out resistant receptor responses. 
3.4. Kinetic Probe Competition Assay 
Indirect kinetic binding assays measure, in real time, the competition/displacement of 
labelled tracer compounds by unlabeled test compounds in solution. The binding 
kinetic constants of the tracer have to be previously determined in direct kinetic 
measurements so that the kinetic rate constants, kon and koff, of the unlabeled 
compounds can be calculated with a suitable mathematical model [53]. In the course 
of the project, the group of Amaury Fernandez-Montalvan at Bayer Pharma AG 
developed a time-resolved fluorescence energy transfer (TR-FRET) based 
homogenous kinetic probe competition assay (kPCA) that uses proteins and tracers 
labelled with TR-FRET donors and acceptors, respectively [46]. It uses microtiter 
plate readers equipped with the necessary optics to measure TR-FRET, and a 
pump-based injection system to enable fast sample mixing and immediate signal 
acquisition. If a suitable tracer is available, kon and koff parameters can be obtained 
for many compounds with high throughput and kinetic resolution at relatively low 
costs. The principle is applicable to many target classes, including kinases and 
GPCRs [46,47]. 
3.5. Transition State Analysis of the Drug-Target Binding Process 
One of the major challenges associated with predicting binding kinetics is the 
molecular understanding of the interactions between the drug and the receptor in the 
transition state, which has the highest free energy and is therefore difficult to 
characterize. One of the methods applied to study the transition state energies of the 
binding event is the temperature dependence of drug-target association and 
dissociation rate constants. By applying the linear Eyring equation (Equation 1), this 
method gives the entropic and the enthalpic contribution to the activation energy of 
the transition state and therefore constructs a detailed thermodynamic signature for 
the binding of drugs to their targets. 
There have been relatively few studies describing this type of analysis. Klein et al. 
have studied the influence of the DFG flip in FGFR1 kinase on the binding kinetics of 
selected type I (PDA) and type II (Ponatinib) inhibitors [54]. Kinetic analysis revealed 
that although both inhibitors have comparable binding affinities (KD= 7.9 nM for 
Ponatinib and KD = 5.7 nM for PDA), Ponatinib has extremely slow association and 
dissociation rates in contrast to the fast kinetic rate constants of PDA. In addition, the 
thermodynamic signatures for both inhibitors were very dissimilar, with the binding of 
PDA being mostly enthalpically driven, in contrast to the highly entropically driven 
interaction for Ponatinib. By measuring the temperature dependence of the kinetic 
association and dissociation rate constants for PDA and Ponatinib and applying the 
Eyring equation, the authors were able to dissect the thermodynamic signature of the 
binding of both inhibitors to FGFR1. Their structural and dynamic approaches 


































































and type II inhibitors on FGFR1 might be due to the significantly high free-energy 
barrier between DFG-in and DFG-out states. 
Kwon et al. reported a transition state analysis on the biotin and bio-5´-AMP 
dissociation from E. coli biotin holoenzyme synthetase [55]. Mutations in the "glycine-
rich” loop region resulted in impairment of dissociation rates of the complexes. 
Analysis of the temperature-dependence of the rate of biotin dissociation by the 
Eyring method revealed that for the G115S mutant the decrease in the residence 
time was mainly due to a reduction of 6.8 kcal/mol in the enthalpic barrier to 
dissociation compensated by an increase of 3.0 kcal/mol in the entropy change. In 
contrast, the drop of the residence time for the R118G mutant is primarily due to a 
reduction of the transition state entropy. 
The studies described here highlight that a deep understanding of the free energy 
landscape for the binding/unbinding process between a drug and a receptor is 
central to the rational optimization of drug binding kinetics.  
4. Standardizing Data – the K4DD Database 
One of the tasks of K4DD is to develop predictive in silico models for binding 
kinetics. This requires sets of standardized high quality data. When looking into the 
public domain, only small amounts of data on binding kinetics are available. 
Furthermore, mostly only kon, koff and KD values are provided without structured 
information on the respective assay. As outlined above, several different 
experimental methods (assay types) to measure drug target kinetics are available. 
While all of them reveal values for kon, koff and KD, there are also method-specific 
outputs for each of those methods, which need to be considered when using them 
for modelling. The consortium thus agreed to set up a database, which is accessible 
to all project members via a web-based interface (https://db.k4dd.eu). Adding new 
kinetic data to the database is a two-step process. At first, a web form is used to 
enter the experimental conditions and properties of the assay itself (e.g. temperature 
or pH). In a second step, experimentally measured bioactivity endpoints based on 
that assay are entered into a standardized spreadsheet template and then uploaded 
to the web server. This upload also has to include the structures of the chemical 
compounds that were investigated in the experiment (either in SDF or SMILES 
format). Several processing steps transform the uploaded structures into a 
chemically normalized form. This is necessary because the uploaded data is 
automatically linked to already existing compounds and targets in the database. 
Also, this allows sophisticated search queries and makes it easier to integrate data 
into existing third-party data stores. 
For this procedure to work smoothly, standardized upload formats were established 
for a variety of assay types. Until now, such formats have been developed for SPR, 
ATR-FTIR, ITC, radioligand binding, kPCA and enzyme activity assays in close 


































































forward in standardizing kinetic assays, since those are the first data models for 
kinetic assays agreed on and used both by public and private institutions. Also, this 
allows the direct comparison of experimental results from different sources within the 
consortium. Currently, the K4DD database contains more than 8000 individual 
endpoints. 
Since the project focuses on a small number (less than 20) of target proteins, the 
database holds many data points per target. This allows the influence of specific 
experimental factors on kinetics to be studied. For example, it is possible to compare 
the differences in kinetics resulting from the same target being measured at two 
different temperatures or using different chemical buffers. For some targets, the 
database contains experimental data for the same compounds obtained from 
different assay types (e.g. SPR and radioligand binding). This is interesting if 
someone wants to compare different assay types with each other. 
In funded projects, one of the major concerns regarding data management is the 
sustainability of the data. There are numerous examples of databases which were 
set up with grant money and then disappeared once the funding was finished. The 
K4DD consortium decided that integration into an already established and actively 
maintained bioactivity database such as ChEMBL [56] would be the best option to 
guarantee sustainability. ChEMBL is an open, large-scale bioactivity database 
containing millions of bioactivity data points for thousands of targets. ChEMBL also 
constitutes the main source for compound-pharmacology associations in the Open 
PHACTS Drug Discovery Platform (https://www.openphacts.org) [29]. Although its 
focus is currently not on kinetic data, the underlying database schema is, after small 
adaptions, suitable for such data points. Thus, the data format has been extended 
for some method-specific experimental parameters that are reported and otherwise 
could not be modelled. Since a prefilled version of ChEMBL was used as a basis for 
the K4DD database, most of the relevant targets are already correctly annotated. 
Therefore, it is possible to effortlessly link kinetic data with other structural and 
bioactivity data from ChEMBL. At the end of the project, the data in K4DD will be 
made publicly available, most probably via donation to ChEMBL. 
 
5. Structure Kinetic Relationships 
With the increasing knowledge about the importance of binding kinetics for the drug 
discovery and development process, attempts to develop computational models for 
predicting kon and koff values have also been initiated. The first thorough analysis of 
kinetic parameters of small, drug like molecules was undertaken by Miller et al. in 
2012 [57]. He provided distributional statistics of physicochemical properties of 
slow/fast compounds by examining kinetic data from the public domain, and an 
unpublished internal dataset of Pfizer. Apart from this, matched pair analysis for 


































































reported [22,94,95]. These matched pairs studies showed that small changes, like 
introducing methylene linkers [94], halogens [95], bulky hydrophobic groups [96] or 
simple methyl groups [22,97], can drastically change the kinetic profile of an inhibitor. 
Nonetheless, no pattern could be generalized for future guidance from these 
findings. The role of hydrophobicity was recently strengthened by Gaspari et al. [58]. 
With respect to Quantitative Structure Kinetic Relationship (QSKR) first insights were 
obtained from analyzing the influence of structural variations of peptides on kinetic 
parameters. In 2006, Andersson et al. established predictive QSKR models for 
dissociation and association rate constants for peptides binding to the recombinant 
antibody Fab 57P isolated from TMVP (tobacco mosaic virus protein) [59,92]. Clear 
differences between the linear regression models for kon and koff values could be 
observed using physicochemical descriptors like hydrophobicity, size and electronic 
characteristics. As the equations for kon and koff differed significantly in descriptor 
contributions, they hypothesized that different driving forces are involved in formation 
of the ligand receptor complex and in the unbinding of the ligand from its binding site. 
Furthermore, they highlighted the necessity of considering kinetic parameters apart 
from affinity to trigger biological response. Another study on therapeutic peptides 
was conducted by Magotti et al in 2009 (ref). They analyzed the kinetic variations of 
Compstatin analogues binding Complement component 3 (C3). By modifying certain 
residues in the Compstatin peptide, complex stability was improved. They identified 
that increased hydrophobicity of a particular residue was the main contributing factor 
to prolonged dissociation rate. Nevertheless, Magotti et al. noticed that individual 
increases in association rate were often compensated by increased dissociation rate. 
In this context, they pointed to the widely known phenomenon of entropy-enthalpy 
compensation that was supported by their biophysical measurements [93]. 
In a recent study, Vilums et al. reported a 56-fold increase in residence time within a 
congeneric series of cyclopentylamines inhibiting chemokine receptor 2 (CCR2) [98]. 
The selection of structural variations was led by observed structure kinetic 
relationships. In addition, they discovered that changes in chirality had a big impact 
on kinetic rates. 
Despite these recent activities, knowledge is restricted to small congeneric series or 
matched pairs on certain targets. The scientific community is lacking thoroughly 
validated, predictive QSKR models for prospective design of drug-like molecules in 
terms of kinetic parameters. One contribution to this current scenario might be the 
absence of appropriate kinetic datasets for the deployment of high level QSKR 
methodologies. The K4DD consortium noticed this gap and is generating appropriate 
kinetic datasets for relevant drug targets. Computational partners within the 
consortium conduct QSKR studies on these datasets in order to identify general 
relationships between structural and/or physicochemical properties and kinetic 
parameters. The resulting QSKR models should guide the medicinal chemist in their 


































































6. Mechanistic Simulation Approaches to drug binding kinetics 
Another approach to computing drug-protein binding kinetics, recently reviewed in 
[62], is to use molecular dynamics (MD) and Brownian dynamics (BD) simulation 
techniques. 
Recent advances in computer technology, such as the use of programmable 
graphics processor units (GPUs), volunteer distributed computing initiatives [63] and 
dedicated computing architectures [64], have increased the speed of conventional 
MD simulations with classical all-atom models into the millisecond timescale and 
contributed to the growing feasibility of ’brute-force’ simulation of the binding of low 
molecular weight compounds to a macromolecular target [65]. Statistical counting of 
association events can be used to estimate kon values [20]. Simulation of ligand 
unbinding is more computationally demanding and has only been achieved with 
conventional MD for weak binders (0.2 and 20 mM) [66]. 
Accurate drug-protein binding/unbinding kinetic constants can be formally obtained 
by the construction of kinetic network models, also called Markov state models 
(MSMs), of the kinetically meaningful metastable states and their transition 
probabilities during the binding process [67]. This approach requires simulations of 
both binding and unbinding events and has only been demonstrated for small 
molecules with relatively fast kon (> 10
7 M⁻1s⁻1) and koff (> 10
2 s⁻1) values [63,67] and 
for targets whose binding site can practically be considered rigid. There are several 
reasons for this. Firstly, the aggregate simulation time required to estimate 
association events is at least the timescale of the corresponding process under 
standard conditions. Therefore, given that a small-sized MD simulation system 
consisting of one small globular protein, for example HIV-1 protease, and one ligand 
in a solvated cubic box of 55x55x55 Å³ (50,000 atoms) has a concentration of ~0.01 
M, a single binding event with kon ~ 10⁶ M⁻
1 s⁻1 would only be expected to be 
observed after a time of about τ = 100 µs. The generation of multiple events from 
which a kon value could be statistically estimated would require at least one order of 
magnitude greater sampling (τ =1 ms).  
This problem can be partially overcome by adaptive sampling methods by which the 
MSM is iteratively computed with re-initiation of simulations into less well explored 
regions of the collective variable (CV) space [65]. This leads to more efficient 
sampling of the space and thus faster convergence of the computed kinetic 
parameters. Similarly, identification of the CV space corresponding to slow timescale 
motions [68] can reduce the required simulation time, taken together, by an order of 
magnitude. However, simulation timescales still remain computationally prohibitive 
for single drug-protein calculations let alone multiple drug screens. Moreover, 
increasing system size, as required when simulating larger proteins, such as 
kinases, or membrane proteins, such as GPCRs [69], substantially increases 
computational demand. This problem is compounded by the fact that such targets 


































































both the binding kinetics and the shape of the active site [70] and often themselves 
require sizeable drugs with substantially greater degrees of freedom (more rotamers, 
increased conformational flexibility) than so far simulated by conventional MD to 
compute kinetic parameters. 
Given that such targets are predominant in drug discovery and relevant binders have 
kon values that are often in the range of 10⁴ – 10⁵ M
-1s-1 [71], conventional MD 
methods are still several orders of magnitude away from routine calculation of drug-
binding kinetics for clinically relevant inhibitors; rather they remain more suited to 
high throughput fragment screens (Figure 4) [72]. 
Brownian dynamics (BD) simulations provide an alternative path to calculating the 
kinetics of drug-protein association by offering a number of simplifying assumptions. 
The drug binding process can be considered in terms of two sub-processes: the 
formation of a metastable diffusional encounter complex followed by an induced fit of 
both receptor and ligand conformations towards the final bound state. When the 
reaction is diffusion-limited [74], simulating the first step is sufficient to compute kon 
[62]. In this regime, the internal motion of the solutes can often be neglected and the 
solutes treated as rigid bodies diffusing in implicit solvent (IS). The kon value can be 
computed by performing a large number of simulations of receptor-ligand association 
to calculate the probability that an encounter complex is formed [75]. Furthermore, 
by exploring the spatial distribution of the ligand around the receptor, BD simulations 
can be used to estimate the relative residence time of encounter, which gives insight 
into the binding mechanism and the determinants of the ligand residence time [76]. 
Such approaches offer a computationally efficient way to calculate even slow 
association rates but major challenges in BD approaches are how to define 
formation of encounter complexes and how to treat the effects of internal motion. 
Furthermore, specific interactions by individual water molecules and/or ions can also 
influence binding kinetics [22,77,78], and are not accounted for in IS models. 
In order to bridge the gap between the current capabilities of all-atom MD and slower 
kinetic regimes, several methods are being explored. 
 
6.1. Multiscale Methods Coupling BD to MD 
Combining rigid-body BD with flexible all-atom MD is a promising approach to 
explore slow conformational gating. Early work by Luty et al. [79] imposed coupling 
at small ligand-receptor (L-R) distances, whereas more recent approaches assume 
discrete conformational changes of either L or R [80,81], whilst the 'BDflex' algorithm 
[82] separates internal and external ligand regions but uses a coarse-grained, CG, 
representation of molecules  to achieve computational feasibility. Another approach, 
based on the original spatial separation of Luty et al., couples BD to an MD region 


































































alternative to MSMs for calculating transition probabilities [84]. The first hitting point 
distribution rather than the equilibrium distribution is used as the starting phase of 
spatial points for the milestoning trajectories. This approach is promising but so far 
has only been applied to idealized small systems like sodium ion binding [83]. 
Furthermore, the milestone surfaces are rather simple – usually concentric spheres, 
and their compatibility with the complexity of ligand structure and dynamics remains 
to be determined. 
 
6.2. Enhanced Sampling Techniques 
Enhanced sampling techniques aim to reduce computational effort by accelerating 
sampling over the relevant degrees of freedom. Methods include metadynamics [85], 
conformational flooding [86], accelerated MD [69,87], and potential-scaled MD [88]. 
All such methods impose a potential bias on the system enabling it to visit less 
energetically favorable states with higher frequency. Whilst the free energy 
landscape can be recovered, such methods distort time thus preventing direct 
retrieval of the kinetic parameters. However, recently a method has been 
implemented that determines the acceleration factor [89], thus enabling recovery of 
kinetics. One challenge is that care has to be taken when recovering the kinetics 
because deposited potentials close to the transition barrier can adversely affect the 
dynamics and thus the transition probabilities. Another drawback of this class of 
methods is that knowledge of the relevant CV subspace is required in advance, in 
order to apply the biasing potential(s). If the CV subspace is not known, it still has to 
be chosen - then a priori, there is no guarantee that the chosen subspace captures 
the relevant kinetic transitions. Recently, however, a CV-independent method has 
been put forward based on potential-scaled MD simulations [90]. Introducing the 
software Biki (www.bikitech.com), the method is aimed at prioritizing compounds 
according to their residence time using multiple replica simulations and statistical 
analysis. Its application is, however, limited to targets whose binding site can be 
considered as rigid, since the protein motion is restrained in order to prevent protein 
unfolding. Recently, Cavalli et al have applied potential-scaled MD simulations to a 
series of glucokinase activators. Results indicate that the ligand shape might 
influence induced fit and thereby have an impact on the residence time. Additionally, 
specific residues influencing residence time were identified [91]. 
A combination of data-based approaches using machine learning techniques with 
structure-based mechanistic modelling might provide a new strategy for prediction of 
drug binding kinetic rates. MD-based methods can reveal particular protein residues 
and protein-ligand contacts that affect association and dissociation barriers, and 
thereby provide kinetics-specific descriptors for QSKR models. Furthermore, the 
development of reliable mechanistic simulation methods might extend the variety of 


































































7. Translating in vitro to in vivo 
A detailed study that highlights the complexity of binding kinetics and links them to in 
vivo effects was recently published by Ayaz and colleagues. They analyzed the 
binding of a series of Roniciclib analogues to different CDKs to assess their 
structure-kinetics relationships [60]. Variation of the substituent at the 5-position of 
the pyrimidine scaffold resulted in changes of up to three orders of magnitude in the 
drug–target residence time (Figure 5). Trifluoromethyl substituted compounds show 
three times longer residence times on CDK2/Cyclin A than on CDK9/Cyclin T in the 
range of hours. X-ray crystal structures revealed that the introduction of the apolar 
trifluoromethyl group into the aminopyrimidine scaffold induces a rearrangement of 
the hydration network. This seems to be accompanied by a conformational adaption 
of the DFG loop, likely giving rise to the prolonged pCDK2/cyclin A residence time of 
Roniciclib which is almost one order of magnitude greater than that of the 5-bromo 
analogue. The trifluoromethyl substituted compounds show superior efficacy in tumor 
growth inhibition relative to the corresponding 5-bromo analogues despite their 
similar in vitro kinase inhibition activity and cell proliferation IC50 values [61]. In 
tumor cells, the prolonged residence time of Roniciclib on CDK2 is reflected in a 
sustained inhibitory effect on retinoblastoma protein phosphorylation, indicating that 
the target residence time on CDK2 may contribute to sustained target engagement 
and antitumor efficacy. Hence, it appears likely that for antitumor efficacy driven by 
CDK inhibition, an increased target residence time on CDK2 and CDK9 positively 
contributes to efficacy by sustained inhibition of CDK signaling. 
However, to understand the impact of in vivo drug-target binding kinetics on the time-
course of target occupancy and drug effect, one should realize that drug-target 
binding is only one aspect of the causal chain from drug dosing to drug effect [99]. 
Other aspects include: 
 The concentration profile of the free drug in plasma and at the target site 
(pharmacokinetics, rebinding) [26,100] 
 Non-specific binding in plasma and target tissue [101] 
 The concentration of the target [26] 
 Competition between drug and endogenous ligand binding [14,15] 
 Target turnover [23], [102] 
 Signal transduction [103] 
 
These factors can all influence the ultimate importance of drug-target binding 
kinetics, thus putting the binding kinetics in the in vivo context. Therefore, these 
factors need to be taken into account in the translation from in vitro to in vivo target 
binding [104]. 
The best way to get information on the relevant factors in the in vivo context is to 


































































determined this way but in vivo experiments allow for the measurement of free and 
total drug concentration-time profiles in plasma and in target tissue. This is especially 
important when the target is located in a tissue protected by restrictive barriers, such 
as the blood-brain barrier. The distinction between total drug concentration in a 
reference tissue without the drug target and the respective target tissue provides 
information on the specific target binding. To that end, experiments should include 
the measurement of drug concentration at steady state conditions (extent of 
distribution) and at different equilibration times (rate of distribution). Microdialysis is 
the best possible technique to measure the free concentration-time profiles at the 
target tissue in individual animals (or humans; except for brain), while post-mortem 
tissue homogenate (at multiple time points, using multiple animals) can be used to 
measure total tissue concentration (being the sum of specific target binding and non-
specific binding to other cellular components). Quantification of drug concentrations 
can then be performed with radioactivity-based or non-radiolabeled, LC-MS based 
methods [104]. The data obtained from the in vivo experiments can be further used 
in mathematical modelling to derive the target occupancy as a function of time. The 
group of Liesbeth de Lange at Leiden University has applied this methodology to 
unravel the relationship between pharmacokinetics, drug-target binding kinetics and 
target occupancy of non-radiolabeled dopamine D2 antagonists and agonists (Figure 
6). Based on the in vivo drug concentration-time profiles in different brain 
compartments and in vitro kon and koff values at the D2 receptor, a mechanistic model 
incorporating these three factors is required to assess the impact of binding kinetics 
on the brain D2 receptor occupancy-time profile. 
Another approach is to get insight into the binding kinetics use modelling in an in vivo 
context is to use mathematical modelling and simulations. Especially the insight into 
the rate limiting step in the time-course of in vivo target occupancy is of high value. 
Predictions of in vivo target occupancy made on the basis of such simulations should 
then be validated by performing specific in vivo experiments. Deviations from 
predictions can be used to improve the model and the insight. For example, in a 
simplified situation with only elimination, distribution and target binding of the free 
drug, target binding of the free drug, the duration of target occupancy is determined 
by elimination rate of the drug from plasma, the distribution of the drug from tissue to 
plasma or by drug-target dissociation rate. When the rate of all these processes is 
known, the duration of target occupancy can be predicted by taking into account that 
the slowest of these processes is most influential in determining the duration of 
target occupancy. 
As commonly acknowledged, the time course of target occupancy is influenced by 
the free plasma concentration, as it drives drug-target binding.  However, drug-target 
association also decreases the free plasma concentration, whereas drug-target 
dissociation increases the free plasma concentration. This influence of binding on 
free drug concentrations in plasma has been described for many biologics and a few 


































































and has been clearly illustrated for a series of small-molecule HSP90 inhibitors [107]. 
The influence of this mutual interaction between target binding and free 
concentrations is influenced by: 
 the amount of target available for binding 
 the drug-target binding kinetics (kon, koff) and affinity (KD) 
 the elimination rate of the drug from the plasma 
Further analysis of this interaction reveals an important role for the value of kon to 
determine both the duration of target occupancy and the concentration profile of free 
drug near the target. This influence of kon for high affinity drugs can be clearly seen 
in the simulations in Figure 7, where kon is the only changing parameter between the 
different simulations (line colors). 
If target binding occurs in a separate (sub)tissue, the interaction between target 
binding and free drug concentrations in the tissue leads, for high values of kon, to a 
slower decrease of drug concentrations in the tissue, compared to the decrease of 
plasma concentrations. A longer duration of target occupancy, also for fast 
dissociating drugs, should be expected for drugs with high values of kon. This 
influence of target binding on the free drug concentration near the target has also 
been described in terms of “rebinding” [26]. An integrated analysis of the influence of 
drug-target binding kinetics, plasma pharmacokinetics and local drug concentrations 
has recently revealed the role of binding kinetics on target occupancy duration from 
a comprehensive analysis of the rate-limiting step in this system [108]. This analysis 
shows both the need and the opportunities for an integrated analysis of the relevant 
determinants of target occupancy and effect, including drug-target binding kinetics. 
 
8. Residence Time as a Decision Criterion 
It is often necessary to measure for long periods of time to determine the residence 
time of drugs, which substantially reduces throughput. However, it may not be 
necessary to determine the exact residence time of drugs. In addition, experimental 
assay formats that do not attempt to measure the exact residence time but rather the 
relative residence time of ligands have much higher throughput. By doing this in a 
pseudo-quantitative way, this could still give a lot of information. Therefore it might 
be useful to change the assay format by establishing a cut off value and divide drug 
candidates into fast and slow dissociating ligands. In terms of prolonged occupancy, 
which is considered a benefit of long residence drugs, the limiting factor will be that 
at some point drugs stay bound for the entire lifespan of a protein. Re-synthesis of 
unbound receptor will therefore determine how long the drug has an effect after 
elimination of the unbound drug from the body [23].  
As discussed, there is often limited throughput in which ligand binding kinetics for a 


































































deal with low throughput is to use a limited set of time points [109,110]. As a trade-
off for this increased throughput, the exact dissociation rate can no longer be 
determined and instead arbitrary metrics are used to quantify the relative differences 
in binding kinetics. Therefore, the comparison with other datasets is limited and this 
can only be partially solved by including reference compounds in the test-set to 
obtain comparative data. 
For example, more than 1800 antagonists were evaluated for their relative 
dissociation rates from the D2R [110]. To do so, membranes expressing the receptor 
were pre-incubated with antagonist. Consecutively, membranes were separated from 
unbound ligands using filtration and membranes were then incubated with 
radioligand. The rate of dissociation from the D2R of the unlabeled ligands 
determines the available receptors for binding the radioligand, which is evaluated 
after a 5 min incubation time. The amount of radioligand is therefore an indirect 
measure, distinguishing between unlabeled ligands with various degrees of 
dissociation within this 5 min incubation time. However, theoretically, the incubation 
time could be easily tailored to reflect the differences in residence time for any 
relevant timespan. 
A major drawback of such an approach is the required knowledge of the optimal 
drug-target residence time. If it was known what drug-target residence time would be 
required to elicit an in vivo response, it would be an excellent incubation time in the 
above example for ranking the relative drug-target residence times. However, 
research describing the effects of the respective drug-target residence time in vivo is 
lacking, making it often unclear what the desired residence time would be. 
A popular rationale for increasing the residence time in the literature is to retain a 
prolonged receptor occupancy after the clearance of unbound drug [2,3,111]. As 
mentioned above, a long duration of drug-action in vivo is not just dependent on the 
drug-target residence time. However, in cases in which drug-target residence time 
could increase the therapeutic window, effectiveness would also depend on the rate 
at which new unbound drug target is synthesized and degraded, subsequently 
lowering the occupancy of the total receptor population. For example, it was shown 
in vitro and in vivo that the inhibitor of BTK1, despite its 167 hours residence time 
had a >50% reduction in occupancy within a day due to re-synthesis of the kinase 
[112]. Increasing the drug-target residence time far beyond the time needed for re-
synthesis of the target will therefore not lead to an increasing therapeutic window. 
Another example where drug-target residence time could make a difference is for 
drug-targets that can be antagonized in an insurmountable fashion. This can occur 
when the presence of the agonist is transient (e.g. neuronal signaling), enabling the 
long-residence time antagonist to outlast the presence of the agonist while bound to 
the target [15]. In this way, signaling will be blocked by the antagonist even when 
there are very high concentrations of agonist. However, once an antagonist would 


































































the pulse of agonist exposure, a further increase in residence time will not improve 
the in vivo activity, unless the agonist pulse is repetitive and the elimination of 
unbound drug is faster than the dissociation. Pinpointing the required residence time 
is not just dependent on the timing and frequency of the agonist pulse but also on 
the number of receptors and transduction efficiency, which will be cell type 
dependent [113]. Therefore, determining the minimum residence time for complete 
insurmountable antagonism might not be as straightforward. 
In conclusion, long residence time drugs might have a kinetic advantage in vivo, but 
if this advantage is at some point limited by the biological system, a further increase 
of the residence time would be worthless. Hence, the relation between the kinetics of 
drugtarget binding and its imposed effect in vivo requires much more attention. 
Breakthroughs here will not only help in establishing selection criteria in early drug 
discovery, but as discussed it could also enhance the throughput with which 
information can be obtained by using arbitrary metrics describing the underlying 
drug-target binding rate constants. This would also make it easier to use functional 
assays for drug optimization in which it is difficult to quantitatively determine the 
binding rate constants of drugs, but easier to measure the relative effects on 
signaling [52,114]. Moreover, when using functional assays to measure the duration 
of action of a test-set of ligands, this could already capture some of the biological 
limits, which arguably could be more valuable information for drug optimization then 
just the drug-target residence time. 
Summary and Outlook 
For decades, drug discovery and development has been focused on optimizing 
binding affinity while essentially neglecting drug binding kinetics. In recent years, it 
has become evident that in vitro information on drug target binding kinetics is of 
utmost importance in candidate compound selection. However, in vitro information 
should be accompanied by information on the in vivo context in which the drug 
needs to exert its ultimate effect. While target degradation/internalization, the 
concentration of the target, and endogenous competition might be difficult to assess, 
important insights into the role of binding kinetics can be obtained by investigating in 
vitro binding kinetics (kon, koff). This can be done in conjunction with measuring the 
free and total concentration-time profile of the drug in plasma and (sub)tissue(s) the 
binding rate constants can identify the rate limiting step in the target occupancy 
profile. Due to the complexity of the factors determining drug binding kinetics, a 
multilevel approach is necessary with both in vitro and in vivo experiments as well as 
computational modelling. Public-private partnerships, such as the K4DD project, are 
well suited to targeting drug binding kinetics in a holistic way and to providing new 
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Figure 1: A combination of experimental and computational approaches are used in the in 
the K4DD consortium to study drug binding kinetics and learn about structure-kinetics 
relationships [28] 
 
Figure 2: View of five antagonists in the binding site of the A2AR receptor. ZM241385 and 
compound 12x have a long residence time at the A2A receptor and stabilize the salt bridge 
His264-Glu169 (Adapted from [49] Segala J. Med. Chem. 2016) 
 
Figure 3: Schematic representation of the three kinetic assays. A) radioligand binding 
studies. Assay requirements are cell membrane preparations and a high affinity radiolabeled 
tracer. Over time, the unlabeled ligand of interest will displace the radiolabeled tracer and 
from this the kon, koff and residence time (RT) values of the unlabeled ligand can be 
calculated. B) TR-FRET™ assay. Assay requirements are whole cells with a SNAP-tagged 
receptor and a high affinity fluorescent tracer. When the fluorescent tracer and tagged 
receptor are in close proximity, a FRET signal can be detected, over time the unlabeled 
ligand of interest will displace the fluorescent tracer and from this the kon, koff and RT values 
of the unlabeled ligand can be calculated. C) label-free xCELLigence assay. Assay 
requirements are whole cells, no tracer or labeling necessary. Receptor activation can be 
followed over time by monitoring the cell morphology through impedance. Purple circle is a 
fast dissociating ligand, pink circle is a slowly dissociating agonist 
 
Equation 1: Linear Eyring equation, where h and kB are the Planck and Boltzmann 
constants, k is either the association rate constant (kon) or the dissociation rate constant 
(koff). ΔH
# and ΔS# are the changes in enthalpy and entropy of the transition state, 
respectively. T is the absolute temperature and R is the gas constant 
 
Figure 4: A) Kinetic landscape showing the timescale gap between computationally 
accessible (blue) small molecules (based on conventional molecular dynamics of fragment 
binding to Trypsin [73]) and clinically relevant (red) compounds (in this case, several FDA 
approved and trial inhibitors of HIV-1 protease [71]). B) Different strategies required for 
improvement of KD, kon, and koff values (yellow, orange, and red arrows, respectively) 
 
Figure 5: Residence time of 5-substituted Roniciclib analogues; a) Modification of the R5-
group on the sulphonamides. b) Residence time (Τ) of compounds 6-10 on pCDK2/cyclin A 
and pCDK2/cyclin E (SPR experiment at 25°C). c) Substitution at the 5-position on the 
aminopyridine (van der Waals volumes with corresponding topological nonpolar surface 
areas (TNSA)) 
Reprinted from “Conformational Adaption May Explain the Slow Dissociation Kinetics of 


































































CDK9”, ACS Chem Biol 2016, 11, 1710−1719;  Ayaz P, Andres D, Kwiatkowski DA, Kolbe 
C-C, Lienau P, Siemeister G, et al.; With permission of ACS. 
 
Figure 6: LC-MS based approach for exploring in vivo target occupancy-time profile, using 
dopamine D2 receptor ligands as paradigm compounds. After dosing the animal with the 
ligand, plasma, tissues and microdialysate ligand concentrations are quantified by LC-MS. 
The difference in ligand concentrations between target tissue and reference tissue 
represents the specific ligand-target binding. Alternatively, target occupancy could also be 
estimated from the unbound ligand concentration at the target site (obtained from continuous 
microdialysis sampling) and the kon and koff values obtained from in vitro studies. A 
mechanistic computational model can then be constructed to predict the impact of binding 
kinetics and other factors (e.g. ligand dosing regimen) on target occupancy-time profile. 
Assessment of target pharmacokinetics and occupancy using LC-MS based approach offers 
several advantages over radioligand-based imaging approaches like PET and SPECT  [104]. 
Most importantly, it provides higher throughput for drug screening and preclinical 
development, and the interferences due to radioactive metabolites and the anesthetic 
procedures during imaging could be avoided. PK, pharmacokinetics; TO, target occupancy 
 
Figure 7: Model simulations demonstrating that increasing affinities result in higher free drug 
concentrations (lower panel) and longer target occupancies (upper panel), while koff is 
constant. In these simulations, the first-order elimination rate constant kel = 1 h
-1, koff = 36 h
-1 
and the target concentration is 1 nM. The simulated drug dose is relative to the KD. Right: 
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Kinetics for Drug Discovery – An industry driven 
effort to target drug residence time 
 





 An industry driven private-public partnership targets drug binding 
kinetics in a multilevel approach 
 New experimental approaches for measuring drug residence time are 
presented 
 Standardized data formats will guarantee sustainability of the data 
generated 
 Progress in quantitative structure-kinetics relationships as well as 
mechanistic simulation approaches are discussed 
 Transition from in vitro to in vivo is key for adoption of the residence 
time as decision criterion in drug development  
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